Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 80.6%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 4,812 shares, a decrease of 80.6% from the July 30th total of 24,819 shares. Based on an average daily trading volume, of 118,901 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.5% of the company’s shares are short sold.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned approximately 14.71% of Biodexa Pharmaceuticals at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biodexa Pharmaceuticals currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 14.7%

BDRX stock opened at $1.01 on Wednesday. Biodexa Pharmaceuticals has a 12-month low of $0.99 and a 12-month high of $59.40. The company has a 50 day moving average of $2.05 and a two-hundred day moving average of $3.35.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.